Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 544 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resected Stage Clear all
Completed Phase 2 Interventional

Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery

NCT00961090
View directory record Official record
Conditions
Glioblastoma
Interventions
Aminolevulinic Acid
Drug
Lead sponsor
Matthew R Quigley
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 23, 2026, 1:24 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults

NCT07463378
View directory record Official record
Conditions
Wound Healing, Acute Skin Wounds
Interventions
LUT017,Topical BRAF inhibitor
Drug
Lead sponsor
Antoni Ribas
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 1:24 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

NCT01280344
View directory record Official record
Conditions
Gastrointestinal Dysmotility
Interventions
Saline Solution for Injection, Ipamorelin
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
45
States / cities
Florence, Alabama • Sheffield, Alabama • Fountain Valley, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 23, 2026, 1:24 PM EDT
Recruiting Phase 2 Interventional

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

NCT07037004
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Clostridium butyricum CBM588 Strain, Computed Tomography, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 1:24 PM EDT
Not listed Phase 2 Interventional

Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer

NCT00024271
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
recombinant interferon gamma, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, mitomycin C, conventional surgery, hyperthermia treatment, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 23, 2026, 1:24 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer

NCT00003332
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cisplatin, gemcitabine hydrochloride, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 23, 2026, 1:24 PM EDT
Recruiting Phase 2 Interventional

Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

NCT04067830
View directory record Official record
Conditions
Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Best Practice, Laparoscopic Surgery, Quality-of-Life Assessment, Questionnaire Administration, Respiratory Muscle Training Device, Video-Assisted Thoracic Surgery
Other · Procedure · Device
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers

NCT00660699
View directory record Official record
Conditions
Cholangiocarcinoma Cancer, Gallbladder Cancer, Pancreatic Cancer, Ampullary Cancer
Interventions
Gemcitabine, Docetaxel, Radiation
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 23, 2026, 1:24 PM EDT
Terminated Phase 1 Interventional Results available

The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study

NCT05229653
View directory record Official record
Conditions
Endometriosis, Post Operative Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 23, 2026, 1:24 PM EDT
Terminated Phase 2 Interventional Results available

Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme

NCT01575275
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
aminolevulinic acid, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Michael Vogelbaum, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 23, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

NCT01927744
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Erlotinib, Placebo, Questionnaires, Phone Call, Chemotherapy
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 23, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

Study of Diclofenac Capsules to Treat Dental Pain

NCT00985439
View directory record Official record
Conditions
Dental Pain
Interventions
Diclofenac Test (lower dose), Diclofenac Test (upper dose), Celecoxib 400 mg, Placebo
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 23, 2026, 1:24 PM EDT
Not listed Phase 2 Interventional

Removal of Endotracheal Tube Secretions Comprehensively Until Extubation

NCT00663637
View directory record Official record
Conditions
Mechanical Ventilation, Pneumonia
Interventions
CAM (Complete Airway Management) Catheters
Device
Lead sponsor
O. M. Neotech, Inc.
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Cape Girardeau, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2008 · Synced Oct 23, 2026, 1:24 PM EDT
Terminated Phase 3 Interventional

Stage IV Surgery Versus Best Medical Therapy

NCT01013623
View directory record Official record
Conditions
Stage IV Resectable Melanoma
Interventions
Surgery, Surgery plus 2 adjuvant doses of BCG, best medical therapy
Procedure · Other
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 23, 2026, 1:24 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

NCT00085189
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Mucosal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIC Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
Interventions
gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen, multi-epitope melanoma peptide vaccine, incomplete Freund's adjuvant, Montanide ISA 51 VG, agatolimod sodium, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 23, 2026, 1:24 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain

NCT01116661
View directory record Official record
Conditions
Glioma
Interventions
5-Aminolevuline Acid (ALA)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 72 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 23, 2026, 1:24 PM EDT
Terminated Phase 2 Interventional

Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab

NCT04681677
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM, Recurrent GBM
Interventions
Radiation: Intra-operative Radiation Therapy - IORT, Bevacizumab
Radiation · Drug
Lead sponsor
Xoft, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 23, 2026, 1:24 PM EDT
Withdrawn Phase 2 Interventional

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

NCT01524575
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, ERCC1
Interventions
gemcitabine and oxaliplatin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 23, 2026, 1:24 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Following Pancreatic Surgery

NCT00660270
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pancreatic Surgery, Radiation therapy, Cisplatin, 5-FU, Alpha-interferon, Gemcitabine
Procedure · Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 23, 2026, 1:24 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT04688931
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102, TURBT
Drug · Procedure
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
33
States / cities
Tucson, Arizona • Loma Linda, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 23, 2026, 1:24 PM EDT
Terminated Phase 1 Interventional Results available

Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

NCT03122106
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
Interventions
Personalized neoantigen DNA vaccine, TDS-IM Electrode Array System, Peripheral blood draws
Biological · Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 23, 2026, 1:24 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

NCT00031733
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, sargramostim, tyrosinase peptide, alum adjuvant, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 23, 2026, 1:24 PM EDT
Terminated Not applicable Interventional

Regional Anesthesia and Lung Cancer Recurrence

NCT01179308
View directory record Official record
Conditions
Lung Cancer
Interventions
General-epidural anesthesia, Balanced general anesthesia and postoperative opioids
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 23, 2026, 1:24 PM EDT
Not yet recruiting Not applicable Interventional

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

NCT07254650
View directory record Official record
Conditions
Lung Cancer (Diagnosis)
Interventions
Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 1:24 PM EDT